Ariana Z Turk¹ and Pooja Mohan Rao²*

¹Georgetown University School of Medicine, Washington, DC, USA
²Assistant Professor, Department of Neurology, Georgetown University Hospital, Washington, DC, USA

*Corresponding Author: Pooja Mohan Rao, Assistant Professor, Department of Neurology, Georgetown University Hospital, Washington, DC, USA.

Received: August 20, 2024; Published: September 27, 2024

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterised by upper and lower motor neuron dysfunction. Despite its devastating impact, diagnostic challenges and a limited understanding of disease pathogenesis complicate effective management. Recent advancements in pharmacological therapies offer hope for improved outcomes. This review examines the current treatment landscape for ALS, including Riluzole (Rilutek), Edaravone (Radicava), and Tofersen (Qalsody), with a focus on their mechanisms, clinical efficacy, and implications for patient care. Additionally, we will briefly discuss the approval and subsequent withdrawal of Sodium Phenylbutyrate/taurusodiol (Relyvrio) as well as anecdotal evidence for Dextromethorphan-Quinidine (Nuedexta) and vitamin B12. Patients with ALS are best managed in a multidisciplinary clinic with access to specialists trained in neurology, pulmonology, physical therapy, occupational therapy, and speech therapy, as well as a social worker, an ALS association representative, a dietician and nutritional therapist all of whom contribute to improving quality of life for these patients.

 Keywords: Amyotrophic Lateral Sclerosis (ALS); Upper Motor Neuron (UMN); Lower Motor Neuron (LMN)

References

1. Mehta P., et al. “Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015”. MMWR Morbidity and Mortality Weekly Report46 (2018): 1285-1289.
2. Marin B., et al. “Age-specific ALS incidence: a dose-response metaanalysis”. European Journal of Epidemiology7 (2018): 621-634.
3. Balendra R and Isaacs AM. “C9orf72-mediated ALS and FTD: multiple pathways to disease”. Nature Reviews Neurology9 (2018): 544-558.
4. Sreedharan J., et al. “TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis”. Science 5870 (2008): 1668-1672.
5. Cedarbaum JM., et al. “The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)”. Journal of Neurological Sciences1-2 (1999): 13-21.
6. Schoenfeld DA., et al. “Design and analysis of a clinical trial using previous trials as historical control”. Clinical Trials 5 (2019): 531-538.
7. Bensimon G., et al. “A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group”.
   The New England Journal of Medicine9 (1994): 585-591.
8. Doble A. “The pharmacology and mechanism of action of riluzole”. Neurology 6 (1996): S233-241.
9. Fang T., et al. “Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study”. Lancet Neurology5 (2018): 416-422.
10. Takahashi F., et al. “Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebocontrolled study of edaravone in amyotrophic lateral sclerosis”. Amyotroph Lateral Scler Frontotemporal Degener 18 (2017): 32-39.
11. Writing Group, Edaravone (MCI-186) ALS 19 Study Group. “Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial”. Lancet Neurology7 (2017): 505-512.
12. Singh P., et al. “Edaravone oral suspension: A neuroprotective agent to treat amyotrophic lateral sclerosis”. American Journal of Therapy3 (202): e258e267.
13. Ferrer reports top-line results from Phase III ADORE study in ALS | Ferrer (2024).
14. Abati E., et al. “Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)”. Expert Opinion on Therapy Targets4 (2020): 295-310.
15. Miller T., et al. “Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS”. The New England Journal of Medicine2 (2020): 109-119.
16. Miller TM., et al. “Trial of antisense oligonucleotide tofersen for SOD1 ALS”. The New England Journal of Medicine12 (2022): 1099-1110.
17. Paganoni S., et al. “Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis”. The New England Journal of Medicine10 (2020): 919-930.
18. Paganoni S., et al. “Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis”. Muscle Nerve 1 (2021): 31-39.
19. Nikitin D., et al. “The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council”. Journal of Managed Care and Specialty Pharmacy 2 (2023): 216-221.
20. Oki R., et al. “The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial”. JMIR Research Protocol 12 (2018): e12046.
21. Kaji R., et al. “Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study”. Journal of Neurology, Neurosurgery, and Psychiatry 4 (2019): 451-457.
22. Oki R., et al. “Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial”. JAMA Neurology6 (2022): 575-583.
23. Smith R., et al. “Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial”. Neurotherapeutics 3 (2017): 762-772.

Citation

Citation: Ariana Z Turk and Pooja Mohan Rao. “Amyotrophic Lateral Sclerosis (ALS): Current Treatment Options and Efficacy". Acta Scientific Neurology 7.10 (2024): 13-16.

Copyright

Copyright: © 2024 Ariana Z Turk and Pooja Mohan Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.